322 related articles for article (PubMed ID: 30247102)
21. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
23. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
[TBL] [Abstract][Full Text] [Related]
24. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
[TBL] [Abstract][Full Text] [Related]
25. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
McColley SA; Konstan MW; Ramsey BW; Stuart Elborn J; Boyle MP; Wainwright CE; Waltz D; Vera-Llonch M; Marigowda G; Jiang JG; Rubin JL
J Cyst Fibros; 2019 Jan; 18(1):94-101. PubMed ID: 30146268
[TBL] [Abstract][Full Text] [Related]
26. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
27. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
28. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
Deeks ED
Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
30. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
31. Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
Beattie A; Moore A; Ramagopalan SV
Lancet; 2024 Jun; 403(10444):2591-2592. PubMed ID: 38879249
[No Abstract] [Full Text] [Related]
32. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
33. Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.
Al Shakirchi M; Sorjonen K; Hjelte L; Klingspor L; Bergman P; Ericson P; Svedberg M; Lindberg U; Hansen C; Monestrol I
Ther Adv Respir Dis; 2024; 18():17534666241254090. PubMed ID: 38780228
[TBL] [Abstract][Full Text] [Related]
34. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
[TBL] [Abstract][Full Text] [Related]
35. VO
Wilson J; You X; Ellis M; Urquhart DS; Jha L; Duncan M; Tian S; Harris RA; Kotsimbos T; Keating D
J Cyst Fibros; 2021 May; 20(3):499-505. PubMed ID: 33358691
[TBL] [Abstract][Full Text] [Related]
36. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
37. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
[TBL] [Abstract][Full Text] [Related]
38. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
[TBL] [Abstract][Full Text] [Related]
39. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
40. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
